09:11 AM EDT, 08/03/2026 (MT Newswires) -- British drugmaker AstraZeneca (AZN.L, AZN.ST) officially launched its Imjudo drug in China to help patients with advanced liver cancer, Reuters reported on Monday. The company previously said results from its Emerald-3 Phase III trial showed that combining its Imfinzi, Imjudo, lenvatinib, and transarterial chemoembolization, or TACE, delivered a statistically significant and clinically meaningful improvement in progression-free survival for patients with unresectable hepatocellular carcinoma compared with TACE alone. AstraZeneca did not immediately respond to requests for comment from MT Newswires. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.